Though Biogen Idec is a recognized pioneer in the field of large-molecule biologic-based therapeutics, we are also dedicated to advancing our small molecule programs, several of which are in late-stage clinical trials (Phase 2 or beyond).
Some of our key small molecule program include:
- BG-12 and Fampridine-SR for multiple sclerosis
- BIIB014 for Parkinson's disease
High-impact career opportunities within our small-molecule programs exist in a variety of departments and capacities – including Research, Technical Development, Contract Manufacturing, and CMC. We currently have small molecule openings in Cambridge, Massachusetts (our corporate headquarters) and Zug, Switzerland.